Printout from Pearl Cohen Zedek Latzer Baratz

Biography

Dr. Michael Yamin is a Scientific Advisor in the Life Sciences Group in Pearl Cohen’s New York office. Michael works primarily in patent drafting, worldwide patent prosecution, patent strategy planning, and portfolio management in the life sciences and biotechnology areas. His technical experience includes pharmaceuticals, formulations, small molecules, molecular biology, immunology, biochemistry, pharmacology, and cellular and developmental biology.

Prior to joining Pearl Cohen, Michael worked at various companies in the New York City area, including Angion Biomedica Corp., Warren Pharmaceuticals, Inc., Mojave Therapeutics, Inc., The Picower Institute for Medical Research, Innapharma, Inc., and Alteon Inc. He was also a research associate at The Rockefeller University. Michael is also a member of the board of directors of Angion Biomedica Corp.

 

Admitted

  • U.S. Patent & Trademark Office

Education

Rockefeller University, Ph.D., 1980

University of California, Davis; B.Sc. Bacteriology, 1975

Languages

English

Professional Membership

LES - Licensing Executives Society

AUTM - Association of University Technology Managers

ASBMB - American Society for Biochemistry and Molecular Biology

Publications

1.Paka L, Smith DE, Jung D, McCormack S, Zhou P, Duan B, Li JS, Shi J, Hao YJ, Jiang K, Michael Yamin, Goldberg ID, Narayan P (2017). Anti-steatotic and anti-fibrotic effects of the KCa3.1 channel inhibitor, Senicapoc, in non-alcoholic liver disease. 21; 23 (23):4181-4190.

2.Narayan P, Duan B, Jiang K, Li J, Paka L, Michael Yamin, Friedman SL, Weir MR, Goldberg ID. Late intervention with the small molecule BB3 mitigates postischemic kidney injury. Am J Physiol Renal Physiol. 2016; 1;311(2):F352-61

3.Ueba H, Shiomi M, Brines M, Michael Yamin, Kobayashi T, Ako J, Momomura S, Cerami A, Kawakami M. Suppression of coronary atherosclerosis by helix B surface Peptide, a nonerythropoietic, tissue-protective compound derived from erythropoietin. Mol Med. 2013 Jul 24;19:195-202.

4.Schmidt RE, Feng D, Wang Q, Green KG, Snipes LL, Michael Yamin, Brines M. Effect of insulin and an erythropoietin-derived peptide (ARA290) on established neuritic dystrophy and neuronopathy in Akita (Ins2 Akita) diabetic mouse sympathetic ganglia. Exp Neurol. Dec; 2011; 232(2):126-35.

5.Ueba H, Brines M, Michael Yamin, Umemoto T, Ako J, Momomura S, Cerami A, Kawakami M (2010). Cardioprotection by a nonerythropoietic, tissue-protective peptide mimicking the 3D structure of erythropoietin. Proc Natl Acad Sci U S A. 2010 Aug 10;107(32):14357-62.

6.Brines, M., Patel, N.S., Villa, P., Brines, C., Mennini, T., De Paola, M., Erbayraktar, Z., Erbayraktar, S., Sepodes, B., Thiemermann, C., Ghezzi, P., Michael Yamin., Hand, C.C., Xie, Q.W., Coleman, T., and Cerami, A. (2008) Nonerythropoietic, tissue-protective peptides derived from the tertiary structure of erythropoietin. Proc Natl Acad Sci USA 2008, 105: 10925-30.